Ref ID: 15147
Author:
S. KRISHNAN-NATESAN, S. SWAMINATHAN, P. CHANDRASEKAR
Author address:
Wayne State Univ., Detroit, MI, 2John D. Dingell VA Med. Ctr., Detroit, MI.
Full conference title:
50th Annual ICAAC
Date: 12 September 2014
Abstract:
Background: The high mortality rate and emerging antifungal drug resistance associated with invasive aspergillosis emphasizes the need for novel, more potent fungicidal agents.TIs have not been evaluated against azole-R Aspergillus. Fungal topoisomerases differ from their mammalian counterparts. Aim: To investigate the efficacy of type II TIs (Ciprofloxacin-CIP; levofloxacin-LEV; moxifloxacin-MOX) plus VCZ or POS against VCZ-R A. flavus (n=10) and POS-R A. fumigatus (n=10) Methods: Fresh conidial suspensions were prepared from VCZ-R A. flavus and POS-R A fumigatus, (n= 20; MIC 2-16 mcg/ml). The in vitro susceptibility of Aspergillus to 2-drug combinations of VCZ or POS with CIP, LEV or MOX (0.125-32 mcg/ml) was evaluated using FICI (fractional inhibitory concentration index) and CLSI-M38-A2 method, followed by menadione-augmented MTT (Methyl-thiazolyl tetrazolium bromide) assay. The insoluble blue formazan salt produced by viable hyphae was dissolved in 95% isopropanol and quantitated by spectrophotometry (OD550). Drug interaction was defined as synergistic, no interaction or antagonistic if FICI< 0.5, 0.5-4 or > 4 respectively. Results: TIs alone had no activity (MIC > 512mcg/ml) against Aspergillus. CIP (2 mcg/ml) plus VCZ or POS (0.5-1 mcg/ml) demonstrated synergy against all isolates tested. FICI was < 0.5, < 0.5-1 and < 0.5-1 and reduction in OD550 (reduced formazan production by non-viable hyphae) was ≥ 80%, 60% and 60% for triazoles with CIP, LEV or MOX respectively; > 2-fold decrease in MIC-80 was noted for VCZ or POS with TIs; antagonism was observed with ≥ 128 mcg/ml of TIs. Conclusion: TI plus triazole showed synergy against azole-R Aspergillus. CIP had the best synergy among the 3 TIs studied. Triazoles likely increase fungal cell membrane permeability to TIs; TIs appear to have affinity to fungal topoisomerases and need to be further explored for their potential antifungal activity.
Abstract Number: M-396
Conference Year: 2010
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a